Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neflamapimod in Dementia With Lewy Bodies (DLB)
NCT04001517Phase 2Completed
- Sponsor
- CervoMed
- Start
- Sep 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in dementia with Lewy bodies (DLB) comparing Neflamapimod with Placebo (2 arms). Primary endpoint: Composite Z-score of a Study-specific Neuropsychological Test Battery at 16 weeks. Started Sep 2019; status: completed.
02
Drugs
neflamapimod
03
Conditions
dementia with Lewy bodies (DLB)
Beyond the preview
Go deeper on NCT04001517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04001517.